The ART-SCORE is not an effective tool for optimizing patient selection for DEB-TACE retreatment. A multicentre Spanish study

Pipa-Muñiz, Maria; Castells, L.; Pascual, Sonia; Fernández-Castroagudín, Javier; Díez-Miranda, Iratxe; Irurzun, Javier; Díaz‐Beveridge, Roberto; Senosiain, Maria; Arenas, Juan; Mata, Manuel de la; Turnés, Juan; Monge-Romero, María Isabel; Pérez-Enguix, D.; Bustamante-Schneider, Javier; Otegui, Nora; Pérez, E. Molina; Rodríguez-Menéndez, José Eduardo; Varela, Marı́a

doi:10.1016/j.gastre.2017.05.007

Cited by 5 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[528][529][530][531] Regrettably, their applicability is controversial and such scoring systems probably identify patients who were poor candidates for TACE at baseline, as defined in these guidelines. [532][533][534][535] TACE should not be repeated when substantial necrosis is not achieved after two rounds of treatment or when follow-up treatment fails to induce marked necrosis at sites that have progressed after an initial tumour response. Additionally, TACE should not be repeated upon 'untreatable progression' defined as tumour progression associated with a clinical profile that prevents re-treatment.…”

Section: Treatment Schedulementioning

confidence: 99%

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Galle¹,

Forner²,

Llovet³

et al. 2018

Journal of Hepatology

6,730

4,351

View full text Add to dashboard Cite

Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Hepatocellular carcinoma represents about 90% of primary liver cancers and constitutes a major global health problem. The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.

show abstract

Section: Treatment Schedulementioning

confidence: 99%

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Galle¹,

Forner²,

Llovet³

et al. 2018

Journal of Hepatology

6,730

4,351

View full text Add to dashboard Cite

show abstract

“…However, two studies have recently reported that CSPH is a major negative prognostic factor in patients treated with DEB-TACE 10,20. It should be noted that the OS of this cohort was lower than that at other sites [21][22][23][24][25][26][27][28][29] (Supplementary table 5),, despite similar patient selection, supra-selective procedures and response to therapy. We speculate that although alcohol aetiology is not an independent predictor of survival, alcohol consumption can impair liver function due to acute-on-chronic liver failure 30 or alcoholic hepatitis 31,32.…”

Section: Discussionmentioning

confidence: 73%

The development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug-eluting embolic chemoembolization

Pipa-Muniz

Sanmartino

Mesa

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: A single-centre cohort study was performed to identify the independent factors associated withthe overall survival (OS) of hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization with drug-eluting beads (DEB-TACE). Methods: A total of 216 HCC patients who underwent DEB-TACE from October 2008 to October 2015 at a tertiary hospital were consecutively recruited. The analysis of prognostic factors associated with DEB-TACE complications was performed. Results: The objective response (OR) rate (Modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria) to the first DEB-TACE (DEB-TACE-1) was 70.3%; the median OS from DEB-TACE-1 was 27 months (95% confidence interval (CI), 24-30). In the multivariate analysis, basal Barcelona Clinic Liver Cancer (BCLC) stage and serum alkaline phosphatase were independent factors for survival following DEB-TACE-1. The most important clinical event associated with poor survival was the development of early ascites after DEB-TACE-1 (median OS, 17 months), which was closely related to the history of ascites, albumin and hemoglobin but not to tumour load or to response to therapy. Conclusions: Early ascites post-DEB-TACE is associated with the survival of patients despite adequate liver function and the use of a supra-selective technical approach. History of ascites, albumin and hemoglobin are major determinants of the development of early ascites post-DEB-TACE.

show abstract

“…That is the case in 71 patients with alcohol related cirrhosis with a first episode of hepatic decompensation that are asymptomatic and compensated after alcohol withdrawal. It should be noted that the OS of this cohort was lower than that at other sites [21][22][23][24][25][26][27][28][29] (Supplementary table 6), despite similar patient selection, supraselective procedures and response to therapy. We speculate that although alcohol aetiology is not an independent predictor of survival, alcohol consumption can impair liver function due to acute-onchronic liver failure [30] or alcoholic hepatitis [31,32].…”

Section: Discussionmentioning

confidence: 74%

The development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug-eluting embolic chemoembolization

Pipa-Muniz

Sanmartino

Mesa

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: A single-centre cohort study was performed to identify the independent factors associated withthe overall survival (OS) of hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization with drug-eluting beads (DEB-TACE). Methods : A total of 216 HCC patients who underwent DEB-TACE from October 2008 to October 2015 at a tertiary hospital were consecutively recruited. The analysis of prognostic factors associated with overall survival after DEB-TACE, stressing the role of post-TACE events, was performed. Results: The objective response (OR) rate (Modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria) to the first DEB-TACE (DEB-TACE-1) was 70.3%; the median OS from DEB-TACE-1 was 27 months (95% confidence interval (CI), 24-30). In the multivariate analysis, tumor size, AFP < 100 ng/mL and serum alkaline phosphatase were independent factors for survival following DEB-TACE-1. The most important clinical event associated with poor survival was the development of early ascites after DEB-TACE-1 (median OS, 17 months), which was closely related to the history of ascites, albumin and hemoglobin but not to tumour load or to response to therapy. Conclusions : Early ascites post-DEB-TACE is associated with the survival of patients despite adequate liver function and the use of a supra-selective technical approach. History of ascites, albumin and hemoglobin are major determinants of the development of early ascites post-DEB-TACE.

show abstract

The ART-SCORE is not an effective tool for optimizing patient selection for DEB-TACE retreatment. A multicentre Spanish study

Cited by 5 publications

References 25 publications

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

The development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug-eluting embolic chemoembolization

The development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug-eluting embolic chemoembolization

Contact Info

Product

Resources

About